An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00109057

Enrollment

Registered

2005-04-25

Start date

1998-02-28

Completion date

2004-02-29

Last updated

2013-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer, Advanced malignancies

Brief summary

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF (Avastin) therapy in any Genentech-sponsored Phase I or Phase II cancer study and who did not show evidence of disease progression at completion of the parent study will be eligible for inclusion in this trial.

Interventions

DRUGAvastin (bevacizumab)

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Previous participation in and completion of a Genentech-sponsored rhuMAb VEGF Phase I or Phase II cancer study * No evidence of progressive disease at completion of the parent study * For women of childbearing potential, use of an effective means of contraception * Signed informed consent

Exclusion criteria

* Any unresolved or irreversible rhuMAb VEGF-related ongoing serious adverse events occurring during the parent study * Any history of central nervous system disease (e.g., primary brain tumor or seizures within 12 months of the first infusion on this study), and/or any evidence of brain metastases * Compromised renal or hepatic function, as defined in the parent protocol * Anemia, neutropenia, or thrombocytopenia, as defined in the parent protocol * Pregnancy (positive pregnancy test) or lactation * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored rhuMAb VEGF cancer study * Recent (within 3 weeks of the first infusion of this study) major surgical procedure, biopsy of a parenchymal organ, or significant traumatic injury * Clinically significant cardiovascular disease (e.g., uncontrolled hypertension \[blood pressure of \>160/110 mmHg on medication\], myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia requiring medication, or peripheral vascular disease (Grade II or greater) * Serious, nonhealing wound, ulcer, or bone fracture * Current or recent (within 10 days of the first infusion on this study) use of oral or parenteral anticoagulants or aspirin (except as required to maintain patency of permanent indwelling intravenous \[IV\] catheters) * Inability to comply with study and/or follow-up procedures * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026